Endovascular treatment of calcific lesions of the common femoral artery using atherectomy device associated with scoring balloon angioplasty in diabetic patients with high “major amputation” risk
Restricted accessResearch articleFirst published online June, 2022
Endovascular treatment of calcific lesions of the common femoral artery using atherectomy device associated with scoring balloon angioplasty in diabetic patients with high “major amputation” risk
To investigate the outcomes of patients with calcific lesions in the common femoral artery undergoing endovascular procedures with atherectomy device and scoring balloon angioplasty combined with treatment of steno-occlusive disease of the remaining arterial districts of the lower limb.
Methods
Between January 2015 and December 2018, 11 diabetic patients at high risk for “major amputation”, with calcific lesions of the common femoral artery and ischemic ulcers requiring endovascular treatment were retrospectively evaluated. Technical success was defined as revascularization of the common femoral artery with a residual stenosis lower than 30%. Primary endpoints were an immediate increase of perilesional transcutaneous oxygen pressure (TCPO2) > 40 mmHg, ulcerative lesions improvement up to healing or skin flaps re-epithelialization after minor amputation, limb rescue with rejected major amputation, and resolution of rest pain if present.
Results
The success rate of the revascularization procedures was 100%. No patient underwent surgical conversion. One case of peri-operative bleeding at the brachial access site was observed. There were no cases of arterial dissection or undesired distal embolization. The average baseline value of perilesional TCPO2 was 21.8 ± 9.2 mmHg. The mean TCPO2 value was 57.4 ± 7.2 mmHg three days after the procedure (P < 0.05), and 51.2 ± 9.8 mmHg 15 days after (P < 0.05). Minor amputations were performed in five patients with advanced ulcerative lesions. No major amputations were performed in the follow-up period. At 14 months follow-up, one patient developed new occlusion of the CFA for extension from the external iliac artery and underwent a new endovascular procedure. We observed an overall primary patency rate of 91% and a primary assisted patency rate of 100% in our 18-month follow-up.
Conclusions
Endovascular approach for severely calcified atherosclerotic lesions of the common femoral artery seems to represent a valid therapeutic option associated with promising results in terms of clinical outcome and low complication rates.
NorgrenLHiattWRDormandyJA, et al.Intersociety consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg2007; 45: S5–S67.
2.
FowkesFGR, EHousleyECawoodEHH, et al.Edinburgh artery study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol1991; 20: 384–392. 1991.
3.
KangJLPatelVIConradMF, et al.Common femoral artery occlusive disease: contemporary results following surgical endarterectomy. J Vasc Surg2008; 48: 872–877.
4.
SpringhornMEKinneyMLittooyFN, et al.Inflow atherosclerotic disease localized to the common femoral artery: treatment and outcome. Ann Vasc Surg1991; 5: 234–240.
5.
RutherfordRBBakerJDErnstC, et al.Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg1997; 26: 517–538.
6.
MukherjeeDInaharaT.Endarterectomy as the procedural of choice foratherosclerotic occlusive lesions of the common femoral artery. Am J Surg1989; 157: 498–500.
7.
SilvaJAWhiteCJQuintanaH, et al.Percutaneous revascularization of the common femoral artery for limb ischemia. Cathet Cardiovasc Intervent2004; 62: 230–233.
8.
RogersJHLairdJR.Overview of new technologies for lower extremity revascularization. Circulation2007; 116: 2072–2085.
9.
MeierGH.Current literature for evidence-based infrainguinal endovascular treatment. Semin Vasc Surg2008; 21: 210–216.
PereraGBLydenSP.Current trends in lower extremity revascularization. Surgical Clin North Am2007; 87: 1135–1147.
12.
AzémaLDavaineJMGuyomarchB, et al.Endovascular repair of common femoral artery and concomitant arterial lesions. Eur J Vasc Endovasc Surg2011; 41: 787–793.
WilsonSGelfandDJimenezJ, et al.Comparison of the results of percutaneous transluminal angioplasty and stenting with medical treatment for claudicants who have superficial femoral artery occlusive disease. Vascular2006; 14: 81–87.
15.
OyiboSOJudeEBTarawnehI, et al.A comparison of two diabetic foot ulcer classification systems: The Wagner and the University of Texas wound classification systems. Diab Care2001; 24: 84–88.
16.
HirschATHaskalZJHertzerNR, et al.ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol2006; 47: 1239–1312.
17.
BaumanFRuchMWllilenbergT, et al.Endovascular treatment of common femoral artery obstructions. J Vasc Surg2011; 53: 1001–1006.
18.
BakkerKApelqvistJLipskyBA, et al.The 2015 IWGDF guidance on the prevention and management of foot problems in diabetes. Int Wound J2016; 13: 1072.
19.
AhimastosAAPappasEPButtnerPG, et al.A metaanalysis of the outcome of endovascular and noninvasive therapies in the treatment of intermittent claudication. J Vasc Surg2011; 54: 1511–1521.
20.
MazariFAGulatiSRahmanMN, et al.Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Ann Vasc Surg2010; 24: 69–79.
21.
MehtaMZhouYPatyPS, et al.Percutaneous common femoral artery interventions using angioplasty, atherectomy and stenting. J Vasc Surg2016; 64: 369–379.
22.
WhymanMRFowkesFGKerracherEM, et al.Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication. Eur J Vasc Endovasc Surg1996; 12: 167–172.
23.
GuoJGuoLTongZ, et al.Directional atherectomy is associated with better long term efficiency compared to angioplasty for common femoral artery occlusive disease in Rutherford 2 to 4 patients. Ann Vasc Surg2018; 51: 65–71.
24.
BonviniRFRastanASixtS, et al.Endovascular treatment of common femoral artery disease medium-term outcomes of 360 consecutive procedures. J Am Coll Cardiol2011; 58: 792–8
25.
ThineyPOMillonA, et al.Angioplasty of the common femoral artery and its bifurcation. Ann VascSurg2015; 29: 960–967.
26.
HarrisL.Endovascular treatment of common femoral artery lesions. Eur J Vasc Endovasc Surg2011; 41: 794.
27.
CardonAAilletSJarnoP, et al.long-term results and analysis of failure factors. Ann Chir2001; 126: 777–782.
28.
BonviniRFRastanASixtS, et al.Angioplasty and provisional stent treatment of common femoral artery lesions. J Vasc Interv Radiol2013; 24: 175–183.
29.
LairdJR.Endovascular treatment of common femoral artery disease viable alternative to surgery or just another short-term fix. J Am Coll Cardiol2011; 58: 799–800.
30.
StavroulakisKSchwindtATorselloG, et al.Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for common femoral artery atherosclerotic disease. J Endovasc Ther2018; 25: 92–99.
31.
ZellerTLanghoffRRocha-SinghKJ, et al.Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency. Circ Cardiovasc Interv2017; 10: e004848.
32.
GouëfficYDella SchiavaNThaveauF, et al.Stenting or surgery for de novo common femoral artery stenosis. JACC Cardiovasc Interv2017; 10: 1344–1354.
33.
OhkiTKimihikoKHiroyoshiY, et al.Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions. J Vasc Surg 2017; 66: 130–142.e1.
34.
NasrBKaladjiAVentPA, et al.Long-term outcomes of common femoral artery stenting. Ann Vasc Surg2017; 40: 10–18. Apr
35.
LeeMSHeikaliDMustaphaJ, et al.Acute procedural outcomes of orbital atherectomy for the treatment of common femoral artery disease: sub-analysis of the CONFIRM Registries. Vasc Med2017; 22: 301–306.
36.
DerksenWJVerhoevenBAvan de MortelRH, et al.Risk factors for surgical-site infection following common femoral artery endarterectomy. Vasc Endovascular Surg2009; 43: 69–75.
37.
StaryHCChandlerABDinsmoreRE, et al.A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. Am Heart Assoc Circulat1995; 92: 1355–1374.
38.
StaryHCBlankenhornDHChandlerAB, et al.A definition of the intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. Am Heart Assoc Special Rep Circulat1992; 85: 391–405.
39.
StaryHCChandlerABGlagovS, et al.A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. Arterioscler Thromb1994; 14: 840–856.
40.
HerissonFHeymannMFChétiveauxM, et al.Carotid and femoral atherosclerotic plaques show different morphology. Atherosclerosis2011; 216: 348–354.
41.
TepeGBeschornerURuetherC, et al.Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium. J Endovasc Ther2015; 22: 727–733.
42.
LiistroFGrottiSPortoI, et al.Drug-eluting balloon in peripheral intervention for the superficial femoral artery: The DEBATE-SFA Randomized Trial (drug eluting balloon in peripheral intervention for the superficial femoral artery). JACC Cardiovasc Interv2013; 6: 1295–1302.
43.
FanelliFCannavaleABoattaE.Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther2012; 19: 571–580.
44.
WerkMAlbrechtTMeyerDR.Paclitaxel-coated balloons reduce restenosis after femoropopliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv2012; 5: 831–840.
45.
ScheinertDDudaSZellerT.The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-inhuman randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv2014; 7: 10–19.
46.
ParisCLWhiteCJCollinsTJ, et al.Catheter-based therapy of common femoral artery atherosclerotic disease. Vasc Med2011; 16: 109–112.
47.
LinniKUgurluogluAHitzlW, et al.Bioabsorbable stent implantation vs common femoral artery endoarterectomy: early results of a randomized trial. J Endovasc Ther2014; 21: 493–502.
48.
GeigerMDelooseKCallaertJ, et al.Is there already a place for endovascular tratement of the common femoral artery?J Cardiovasc Surg (Torino)2015; 56: 23–29.
49.
GeigerMAGuillaumonAT.Primary stenting for femoropopliteal peripheral arterial disease: analysis up to 24 months. J Vasc Bras2019; 18: e20160104.
50.
CioppaAStabileEPopusoiG, et al.Combined treatment of heavy calcified femoro-popliteal lesions using directional atherectomy and paclitaxel coated balloon: one year single centre clinical results. Cardiovasc Revasc Med2012; 13: 219–223.
51.
DavisTRamaiahVNiaziK, et al.Safety and effectiveness of the Phoenix Atherectomy System in lower extremity arteries: early and midterm outcomes from the prospective multicenter EASE study. Vascular2017; 25: 563–575.
52.
Ochoa ChaarCIKimTISheblFM, et al.The use of embolic protection devices during lower extremity peripheral vascular interventions. Ann Vasc Surg2020; 69: 9–16.
